-
公开(公告)号：US20230212249A1
公开(公告)日：2023-07-06
申请号：US18068506
申请日：2022-12-19
申请人： YUHAN CORPORATION
发明人： Byung Hyun CHOI , In Hwan LIM , Jun Young PARK , Jin Hyoung LEE , Ki Hong KIM , Hae Yong JO , Jun Hwan KIM , Moo Young SONG , Jong Gyun KIM
CPC分类号： C07K14/605 , C12P21/02 , C07K14/50 , C07K19/00 , C07K16/46 , C12N5/00 , C07K2319/30 , C12N15/00
摘要： A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
-
公开(公告)号：US20210188936A1
公开(公告)日：2021-06-24
申请号：US16606279
申请日：2018-04-20
申请人： YUHAN CORPORATION
发明人： Byung Hyun CHOI , In Hwan LIM , Jun Young PARK , Jin Hyoung LEE , Ki Hong KIM , Hae Yong JO , Jun Hwan KIM , Moo Young SONG , Jong Gyun KIM
IPC分类号： C07K14/605 , C07K14/50 , C12P21/02
摘要： A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
-
3.发明公开公开(公告)号：US20240279203A1
公开(公告)日：2024-08-22
申请号：US18618379
申请日：2024-03-27
申请人： Yuhan Corporation
发明人： Sang Ho OH , Jong Gyun KIM , Se-Woong OH , Tae Dong HAN , Soo Yong CHUNG , Seong Ran LEE , Kyeong Bae KIM , Young Sung LEE , Woo Seob SHIN , Hyun JU , Jeong Ki KANG , Su Min PARK , Dong Kyun KIM
IPC分类号： C07D403/04 , C07C303/22 , C07C309/04
CPC分类号： C07D403/04 , C07C303/22 , C07C309/04 , C07B2200/13
摘要： The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
-
公开(公告)号：US20200024318A1
公开(公告)日：2020-01-23
申请号：US15768865
申请日：2016-10-28
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Seul Gi KIM , Sangmyoun LIM , Jong Gyun KIM , Su Youn NAM
IPC分类号： C07K14/50 , C07K14/605 , C07K14/575 , A61P3/04 , A61P3/06 , A61P3/10 , A61P1/16
摘要： The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.
-
公开(公告)号：US20220002368A1
公开(公告)日：2022-01-06
申请号：US17478628
申请日：2021-09-17
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Seul Gi KIM , Sangmyoun LIM , Jong Gyun KIM , Su Youn NAM
IPC分类号： C07K14/50 , C07K14/575 , C07K14/605
摘要： A dual function protein is disclosed. The dual function protein may be prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin. The dual function protein has improved pharmacological efficacy, in vivo duration and protein stability. The dual function protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.
-
公开(公告)号：US20190314452A1
公开(公告)日：2019-10-17
申请号：US16348249
申请日：2017-11-10
申请人： YUHAN CORPORATION
发明人： Han Na HONG , Jun Hwan KIM , Hyun Ho CHOI , Dohoon KIM , Taewang KIM , Se Woong OH , Moo Young SONG , Jong Gyun KIM
摘要： The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein; and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.
-
公开(公告)号：US20180305428A1
公开(公告)日：2018-10-25
申请号：US15768616
申请日：2016-10-28
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
CPC分类号： C07K14/50 , A61K38/00 , A61K38/1825 , A61P1/16 , A61P3/04 , A61P3/10 , C07K2319/30
摘要： The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
公开(公告)号：US20240279296A1
公开(公告)日：2024-08-22
申请号：US18491616
申请日：2023-10-20
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
CPC分类号： C07K14/50 , A61P1/16 , A61P3/04 , A61P3/10 , A61K38/1825 , C07K2319/30
摘要： A fusion protein contains an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
公开(公告)号：US20230021395A1
公开(公告)日：2023-01-26
申请号：US17697655
申请日：2022-03-17
申请人： Yuhan Corporation
发明人： Sang Ho OH , Jong Gyun KIM , Se-Woong OH , Tae Dong HAN , Soo Yong CHUNG , Seong Ran LEE , Kyeong Bae KIM , Young Sung LEE , Woo Seob SHIN , Hyun JU , Jeong Ki KANG , Su Min PARK , Dong Kyun KIM
IPC分类号： C07D403/04 , C07C303/22 , C07C309/04
摘要： The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
-
公开(公告)号：US20220002367A1
公开(公告)日：2022-01-06
申请号：US17478600
申请日：2021-09-17
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
摘要： A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.015 秒)
